Literature DB >> 20455691

Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.

Yolanda Meije1, Manuel Lizasoain, Ana García-Reyne, Pilar Martínez, Virginia Rodríguez, Francisco López-Medrano, Rafael San Juan, Antonio Lalueza, José María Aguado.   

Abstract

Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma. Temozolomide frequently produces profound lymphopenia. We report 2 cases of cytomegalovirus disease that occurred in patients receiving temozolomide therapy and review 4 additional cases reported in the literature. Narrow monitoring with cytomegalovirus antigenemia assay should be considered for recommendation.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20455691     DOI： 10.1086/653011

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  8 in total

1.  Clinically significant CMV (re)activation during or after radiotherapy/chemotherapy of the brain : Correlation with neurological deterioration and improvement upon antiviral treatment.

Authors:  N Goerig; S Semrau; B Frey; K Korn; B Fleckenstein; K Überla; A Dörfler; F Putz; U S Gaipl; R Fietkau
Journal:  Strahlenther Onkol       Date:  2016-05-31       Impact factor: 3.621

2.  Cerebral aspergillosis within new tumour site presents as incidental new brain lesion in patient receiving temozolomide for glioblastoma multiforme.

Authors:  Shiyuan Anabeth Liu; Timothy Sullivan; Clare Bryce; Amy M Chan; Salvatore Cilmi
Journal:  BMJ Case Rep       Date:  2019-05-31

Review 3.  Medical management of brain tumors and the sequelae of treatment.

Authors:  David Schiff; Eudocia Q Lee; Lakshmi Nayak; Andrew D Norden; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-10-30       Impact factor: 12.300

4.  The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells.

Authors:  Susannah Yovino; Lawrence Kleinberg; Stuart A Grossman; Manisha Narayanan; Eric Ford
Journal:  Cancer Invest       Date:  2013-02       Impact factor: 2.176

5.  Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct.

Authors:  Johan Söderlund; Sophie Erhardt; Richard E Kast
Journal:  J Neuroinflammation       Date:  2010-08-06       Impact factor: 8.322

6.  Recurrence of herpes simplex encephalitis associated with temozolomide chemoradiation for malignant glioma: a case report and review of the literature.

Authors:  Mitalee P Christman; Sarah E Turbett; Soma Sengupta; Khamidulla U Bakhadirov; Craig A Williamson; Lakshmi Nayak; Tracey Milligan; Joel T Katz
Journal:  Oxf Med Case Reports       Date:  2014-03-12

7.  Aspergillosis in a patient receiving temozolomide for the treatment of glioblastoma.

Authors:  Rodrigo Ramella Munhoz; Andrea Arvai Pereira Picarelli; Cristina Aparecida Troques Mitteldorf; Olavo Feher
Journal:  Case Rep Oncol       Date:  2013-08-08

8.  Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.

Authors:  Ryutaro Furukawa; Hirokuni Homma; Tomohiro Inoue; Hajime Horiuchi; Kazuhiro Usui
Journal:  Intern Med       Date:  2018-05-18       Impact factor: 1.271
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.